Cargando…

Language across the Lifespan in Fragile X Syndrome: Characteristics and Considerations for Assessment

While it is widely acknowledged that language development is delayed for the majority of individuals with fragile X syndrome (FXS), there has been limited research into how best to assess this area. This study aimed to deepen the understanding of standardized language assessment in FXS by addressing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, Anne, Wang, Angel, Berger, Natalie, Cordeiro, Lisa, Shaffer, Rebecca, Tartaglia, Nicole, Erickson, Craig, Berry-Kravis, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226519/ https://www.ncbi.nlm.nih.gov/pubmed/32260354 http://dx.doi.org/10.3390/brainsci10040212

Ejemplares similares

Delineating Repetitive Behavior Profiles across the Lifespan in Fragile X Syndrome
por: Reisinger, Debra L., et al.
Publicado: (2020)

Examination of Correlates to Health-Related Quality of Life in Individuals with Fragile X Syndrome
por: Coffman, Marika C., et al.
Publicado: (2020)

A Pilot Quantitative Evaluation of Early Life Language Development in Fragile X Syndrome
por: Reisinger, Debra L., et al.
Publicado: (2019)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities
por: Weber, Jayne Dixon, et al.
Publicado: (2019)

Targeted treatments for fragile X syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2011)

The Relationship between Expressive Language Sampling and Clinical Measures in Fragile X Syndrome and Typical Development
por: Shaffer, Rebecca C., et al.
Publicado: (2020)

Executive Function in Fragile X Syndrome: A Systematic Review
por: Schmitt, Lauren M., et al.
Publicado: (2019)

Soy-Based Infant Formula is Associated with an Increased Prevalence of Comorbidities in Fragile X Syndrome
por: Westmark, Cara J., et al.
Publicado: (2020)

Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
por: Albizua, Igor, et al.
Publicado: (2022)

Analysis of a Repetitive Language Coding System: Comparisons between Fragile X Syndrome, Autism, and Down Syndrome
por: Hoffmann, Anne, et al.
Publicado: (2022)

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2022)

Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018)

Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
por: Luu, Skylar, et al.
Publicado: (2020)

A Paradigm Shifting View of Intellectual Disability: A Near Normal Distribution of IQ in Fragile X Syndrome
por: Schmitt, Lauren M., et al.
Publicado: (2023)

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
por: Budimirovic, Dejan B., et al.
Publicado: (2017)

Behavioral inflexibility in fragile X syndrome: Accounts from caregivers and self-advocates
por: Jones, Angelina, et al.
Publicado: (2023)

Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives
por: Lozano, Reymundo, et al.
Publicado: (2022)

Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2012)

Expressive language sampling and outcome measures for treatment trials in fragile X and down syndromes: composite scores and psychometric properties
por: Abbeduto, Leonard, et al.
Publicado: (2023)

Vocabulary comprehension in adults with fragile X syndrome (FXS)
por: Hoffmann, Anne, et al.
Publicado: (2019)

Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome
por: Farzin, Faraz, et al.
Publicado: (2011)

Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
por: Alusi, Ghassan, et al.
Publicado: (2022)

Fragile X targeted pharmacotherapy: lessons learned and future directions
por: Erickson, Craig A., et al.
Publicado: (2017)

A developmental, longitudinal investigation of autism phenotypic profiles in fragile X syndrome
por: Lee, Michelle, et al.
Publicado: (2016)

Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study
por: Budimirovic, Dejan B., et al.
Publicado: (2021)

Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
por: Lee, Anna W., et al.
Publicado: (2018)

X-inactivation in the clinical phenotype of fragile X premutation carrier sisters
por: Hall, Deborah A., et al.
Publicado: (2016)

Erratum to: A developmental, longitudinal investigation of autism phenotypic profiles in fragile X syndrome
por: Lee, Michelle, et al.
Publicado: (2017)

The challenges of clinical trials in fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2013)

Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome
por: McLane, Richard D., et al.
Publicado: (2019)

Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
por: Abbeduto, Leonard, et al.
Publicado: (2020)

Developmental studies in fragile X syndrome
por: Razak, Khaleel A., et al.
Publicado: (2020)

New observations in the fragile X-associated tremor/ataxia syndrome (FXTAS) phenotype
por: Fraint, Avram, et al.
Publicado: (2014)

Correction to: Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
por: Abbeduto, Leonard, et al.
Publicado: (2020)

Open-label add-on treatment trial of minocycline in fragile X syndrome
por: Paribello, Carlo, et al.
Publicado: (2010)

Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome
por: Jonak, Carrie R., et al.
Publicado: (2022)

Emerging pharmacologic treatment options for fragile X syndrome
por: Schaefer, Tori L, et al.
Publicado: (2015)

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

Expression and Characterization of Human Fragile X Mental Retardation Protein Isoforms and Interacting Proteins in Human Cells
por: Zhang, Jiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5ssuhtnvh1f21fneg7u290pknt